Skip to main
LFMD

LifeMD (LFMD) Stock Forecast & Price Target

LifeMD (LFMD) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 29%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LifeMD Inc. demonstrated a robust growth trajectory in its Telehealth segment, achieving a 14% year-over-year increase in active subscribers, culminating in a total of 310,818 by the end of 3Q25. Total revenue reached $60.2 million, reflecting a 12.7% year-over-year growth, with Telehealth revenue specifically growing by 17.4% to $47.3 million, indicating a strong demand for virtual healthcare services. Additionally, the company's gross margin expanded to 87%, showcasing an improved revenue mix that contributes to its positive financial outlook.

Bears say

LifeMD Inc. faces several fundamental challenges that contribute to a negative outlook, including lower-than-projected growth in telehealth revenue, difficulties in acquiring and retaining new patients, and an inability to achieve profitability. The company reported revenue of $60.2 million, which was a 13% year-over-year growth but fell short of consensus expectations, while adjusted EBITDA of $5.1 million represented a 20% increase yet also missed projections. Additionally, the reduction in full-year 2025 revenue guidance, now anticipated to be between $192 million and $193 million, alongside increased competition and potential dilution risks, heightens concerns regarding LifeMD's financial performance and stability.

LifeMD (LFMD) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 29% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LifeMD and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LifeMD (LFMD) Forecast

Analysts have given LifeMD (LFMD) a Strong Buy based on their latest research and market trends.

According to 7 analysts, LifeMD (LFMD) has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LifeMD (LFMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.